The life sciences industry is witnessing a fundamental shift-one that is driven not just by data, but by intelligent automation. Having spent over 17 years working at the intersection of clinical research, data science, and advanced analytics, I have seen how statistical programming forms the backbone of the execution of clinical trials. Yet, despite being so crucial, statistical programming remains one of the most time-consuming, resource-intensive, and error-prone components of clinical development.
With the rise of GenAI, we stand at the threshold of a revolution that may redefine the generation, validation, and delivery of statistical outputs on global clinical programs. This shift is not purely technological but a new operational philosophy underpinned by efficiency, quality, and scientific rigor.
The Growing Pressure on Statistical Programming
Clinical trials are producing volumes of data that have never existed before. If one estimate is to be believed, in the last decade alone, the volume of clinical data has grown nearly fivefold-driven by decentralized trials, real-world evidence, wearable devices, and genomics. Meanwhile, with growing complexity, a set of persistent challenges have faced programming teams:
- Rising demands and tighter deadlines.
- The need for established and consistent results, such as SDTM, ADaM, and TLFs, is increasing.
- Higher demands from regulatory bodies for more traceability and auditable flows of programming.
- Traditional SAS-based programming, though reliable, cannot scale to meet these escalated demands independently. It is here that Generative AI comes in with a strong promise.
How Generative AI Can Automate Statistical Programming?
It is much more than a chatbot or a text generator: generative AI is capable of learning patterns, generating code, interpreting metadata, and creating structured outputs. In the context of clinical trials, this manifests as automation in a number of ways:
- Auto-Generation of SDTM and ADaM Code
GenAI can interpret source datasets and generate draft mapping code in seconds. Early industry pilots have already shown that up to 40–60% of SDTM programming can be automated by using supervised workflows from GenAI.
- Automating TLF Generation
TLFs, which often take up more than 50% of programming effort, can be partially automated through LLMs that are trained on CDISC standards, therapeutic area templates, and historic outputs.
- Documentation & Annotation
AI can auto-generate traceability in programming, one of the bigger issues during audits, as part of the programming sequence.
- Intelligent Error Detection
GenAI models can indicate inconsistencies in datasets, logical mismatches, missing derivations, or validation gaps, improving both speed and quality.
- Cross-Study Standardization
By learning from past research, GenAI systems can apply consistent code patterns and remove variability that occurs when teams work in silos.
The goal is not to replace statistical programmers but to enhance their capabilities such that they can concentrate on quality, oversight, and interpretation rather than on repetitive tasks related to coding.
Industry Developments: The Drive Toward AI-Driven Automation
A number of global currents are accelerating the adoption of technologies.
Creating CDISC tools that leverage artificial intelligence. Vendors are increasingly offering metadata-driven engines, which feature integrated GenAI, to help create and validate datasets.
These developments represent a shift in the sector, going from a period of experimentation to one of practical application.
My Perspective: Why This Transformation Matters
What I have seen time and again in my career, whether managing global oncology and vaccine trials or leading outsourcing strategies at IQVIA, is that the bottleneck is very rarely science; it’s operational complexity.
What GenAI can do is reduce that burden while strengthening scientific integrity.
Throughout my various roles as Clinical Data Scientist, Statistician, and Trial Operations Leader across the USA, UK, EU, Canada, and Asia, one question remained at the core of my pursuits: How do we make clinical research faster, safer, and more reliable?
Automation of statistical programming fits perfectly with this vision to enable the following:
- Faster database lock timelines
- Reduced human error in repeatable programming tasks
- Improved compliance through consistent outputs
- Increased focus on scientific oversight, rather than mechanical coding
Recognition like the Excellence in Healthcare Award for Health 2.0 in Las Vegas, 2025, and participation in global forums such as PHUSE Pune, IASCT, Biotecnika, and Health 2.0 have further reaffirmed my conviction that the next wave of transformation is going to be driven by intelligent automation.
Beyond clinical operations, my mentorship work with organizations like Samhitha, Syncorp, and Oryxion, and volunteer contributions involving the Maharashtra government and vEnsure’s Hospital Operations Excellence Program have taught me the importance of building AI-literate teams ready for this shift.
Obligatory Automation: The Need for Guardrails
Even with automation, human monitoring is still necessary. In fact, it increases it.
The industry must adopt guardrails such as those that help ensure safety and compliance.
- Tracking the origins of all AI-generated code.
- Human-in-the-loop validation workflows are more common.
- Versioning controls for prompts and outputs
- Ethical frameworks that protect patient data
- Continuous model monitoring to avoid drift
Emerging guidance underlines that AI can write the code, but accountability must remain with a human being.
Conclusion
Generative AI is a fundamental breakthrough in statistical programming, helping to overcome current constraints and greatly improve the quality and speed of clinical research. Change is coming, albeit it won’t arrive in a flash.
As data volumes expand and timelines become more demanding, clever automation will be important for clinical operations. Statistical programmers will evolve into the roles of AI supervisor, quality lead, and analytical strategist. Clinical trials will become more versatile, dependable, and efficient. The real beneficiaries of our efforts are the individuals we assist. They’ll begin to access life-saving treatments more quickly. The future of clinical research will depend not on the amount of data we collect, but on how well we can use that data to make judgments.
About Umesh Kumar
Umesh Kumar, Associate Director of Clinical Operations at IQVIA RDS (India) Pvt. Ltd., is a recognized leader in clinical research and healthcare data science. With 17+ years of expertise across AI, ML, big data, biostatistics, pharmacovigilance, and medical writing, he has driven impactful global trials in oncology, diabetes, vaccines, and more. Over the past 8 years at IQVIA, he has provided strategic leadership in outsourcing initiatives and risk-based monitoring. Honored with the Excellence in Healthcare Award at the Health 2.0 Conference 2025 in Las Vegas, his contributions span SOPs, training, publications, and thought leadership. As an author and speaker at global forums, he continues to inspire by blending technology, science, and strategy to advance healthcare innovation.
Umesh was honoured as Mentor of the Year by Mentorcruise and recognised by the government of Maharashtra in Mumbai for his volunteer contributions. His mentoring in the Hospital Operations Excellence Program boosted vEnsure’s credibility, highlighting its commitment to innovation, mentorship, and leadership in healthcare technology.
Advisor to small firms, including Samhitha, Syncorp, and Oryxion, developed AI and ML structured mentoring programs to guide 15+ engineers across career levels, and mentoring to technology startups and individuals, including partnerships with firms like Milestone Soft Solutions, vEnsure, and different CROs.
